HELICON GROUP LIMITED (ASX: HCG) announced today the relocation of its CEO, Mr Peter Abrahamson to Shanghai to oversee the implementation of its China Strategy.
Unilife Medical Solutions Limited ("Unilife" or the "Company") (ASX: UNI) announces the variation of the purchase price terms of the acquisition agreement ('Agreement') pursuant to which the Company acquired all of the issued shares in Integrated BioSciences Inc. ("IBS") in January 2007.
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) today announced the signing of a research collaboration with New Zealand-based Genesis Research and Development Corporation Ltd. (New Zealand Stock Exchange: GEN).
Shareholders of Melbourne-based Biotech Solagran (ASX: SLA) have approved a new investor-friendly approach to executive pay. The plan requires that the most senior Solagran executives put almost all of their income at risk on the basis of the amount of shareholder wealth created under their stewardship. Shareholders voted overwhelmingly to support the introduction of the plan at an EGM held yesterday.
Melbourne Biotech Solagran Limited (ASX: SLA) today announced that the Director of the Pasteur Institute in St Petersburg, Professor Anatoly Zhebrun DSc, has accepted the Board's invitation to visit Australia to discuss recently completed trials in relation to the use of Bioeffective(R) A in the prevention and treatment of Helicobacter Pylori infection.
Life Therapeutics (ASX: LFE) today announced that the company has resolved to appoint an Independent Expert to provide an independent valuation on the proposed transaction with Kedrion S.p.A ("Kedrion"), pursuant to the terms announced on 30 July 2007. This will include an assessment of the value of LFE's equity stake in Kedrion.
Melbourne based Biotech Solagran Limited (ASX: SLA) today announced that arrangements were being put in place in St Petersburg to supply patients outside Russia with its liver disease drug Ropren, consistent with international regulatory guidelines.
